Quote:

---

Foscarnet and Ibalizumab

---

Ibalizumab - FDA approved while mantaining non-transmissable viral load in only 63% of patients.

Quote:

---

Of the 27 patients who completed the 24-week treatment period of TMB-301 in the U.S., all entered TMB-311, where patients continued to receive ibalizumab at 800 mg every 2 weeks for up to 48 weeks. The virologic suppression observed at week 24 was sustained through week 48; median viral load reduction from baseline was 2.5log10 at weeks 24 and 48. In TMB-311, all 15 patients with an undetectable viral load at week 24 maintained suppression to week 48. Another patient in TMB-311 reached less than 50 copies/mL at week 48 after having a detectable viral load at week 24. A total of 17 patients (63%) achieved a viral load less than 200 copies/mL.
https://www.theratech.com/static-files/e970e3...79d9b1b243

---

Foscarnet - used to treat a couple of opportunistic infections in HIV patients but not HIV itself. 33% viral suppression in combination.

Quote:

---

We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.
https://academic.oup.com/cid/article-abstract...05/7420388

---